The FDA has set a Prescription Drug User Fee Act action date for 24 May 2026.

LEQEMBI is currently approved in 53 countries and regions and is under regulatory review in 7 countries. In August 2025, the US FDA approved LEQEMBI IQLIK 360 mg for weekly subcutaneous maintenance ...

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease FDA acti ...

Learn how to self-administer SCIg at home for primary immunodeficiency. Tips on preparation, reducing pain, managing ...

Vitality Urgent Care is now open in Lake Zurich, expanding access to walk in medical care for families and residents in Lake ...

Many peptides are produced either by compounding pharmacies in the U.S. or by an ever-growing number of factories in China. The most serious users tend to get peptides from the latter for both a wider ...

LEO Pharma A/S, a global leader in medical dermatology, today announced it will present 23 scientific posters at Maui Derm ...

A NASA astronaut on the ISS captured the Space Launch System rocket for Artemis 2, a mission that aims to bring four ...

“What to do with a spouse who doesn’t imbibe, who doesn’t like crowds or noisy restaurants, and who doesn’t overindulge on sugary desserts? First off, we jettison the traditions that I, too, can live ...

Magnetic nanoparticles engineered T cells inside living mice and guided them into solid tumors, achieving over 90% tumor ...

Huahui Health announced that China National Medical Products Administration (NMPA) has granted conditional approval to its Libevitug injection for the treatment of chronic hepatitis D virus infection ...

The FDA has accepted for review the sBLA for subcutaneous lecanemab-irmb as a weekly starting dose for Alzheimer disease.